Antifungal vaccine development: where we are, where we are headed

Invasive fungal infections (IFIs) represent a devastating global health crisis, causing millions deaths annually worldwide. This staggering burden disproportionately affects immunocompromised individuals, including those with HIV/AIDS, cancer, patients undergoing chemotherapy and organ transplant recipients. Current therapeutic options remain limited to only five major drug classes, which face increasing pressure from emerging resistance and frequent treatment failures. Consequently, the absence of a commercially available antifungal vaccine represents a critical gap in preventive medicine. This comprehensive review maps the progression from mechanistic immune responses to the latest vaccine platforms, while critically addressing biological and technical constraints inherent in the field. Rather than a simple enumeration of data, this review constructs a conceptual bridge between laboratory discovery and clinical reality. This integrated model is specifically tailored to address the complexities of treating high-risk, immunosuppressed populations. It highlights how emerging strategies, such as trained immunity-based and donor-derived T-cell therapies, may circumvent the inherent challenges of vaccinating the immunocompromised host. By synthesizing recent advances and identifying critical knowledge gaps, this review charts a strategic path forward for this essential field of vaccine research.